Zamansky Dmitry sold $110K of AMWL

Zamansky Dmitry (Chief Product & Tech. Officer) sold 8,442 shares of American Well Corp (AMWL) at $13.00 ($0.11M total) on 2026-10-01.

Original reporting
SEC EDGAR · Zamansky Dmitry
Published Oct 5, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMWL
Bearish
medium confidence
Mentioned
$AMWL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMWLBearishLow
01

Why it matters

The disclosure provides transparency but the modest size limits market impact.

02

Market read

A small insider sale that may cause slight short‑term pressure on AMWL shares.

03

What to watch

The officer's holdings remain sizable, and the sale was executed via an open‑market transaction without a 10b5‑1 plan.

Relevance 4/10Novelty 4/10Timing: post-filing today

Background

SEC Form 4 filing discloses insider transactions required by regulators.

Company-level read

Ticker impact

$AMWLBearishMedium confidence
Context

Chief Product & Tech Officer sold 8,442 shares for $109,746, reducing his stake to 224,178 shares.

Expected impact

likely slight downward pressure as investors price the insider sell

Evidence & confidence

Insider sales, especially by a senior officer, are often interpreted as a negative signal, though the amount is modest.

Market effects

Minimal impact on the broader telehealth sector; the sale is company‑specific.

No discernible regional effect.

Limited to investors tracking AMWL.

Counterpoint

The sale may be routine portfolio rebalancing and not indicative of future performance.

Key entities

  • American Well Corp

    Provider of telehealth services, ticker AMWL.

  • Zamansky Dmitry

    Chief Product & Tech Officer at AMWL.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.